Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;57(1):55.
doi: 10.1186/s41983-021-00310-7. Epub 2021 May 4.

Guillain-Barre syndrome in 220 patients with COVID-19

Josef Finsterer  1 , Fulvio A Scorza  2
Affiliations
Review

Guillain-Barre syndrome in 220 patients with COVID-19

Josef Finsterer et al. Egypt J Neurol Psychiatr Neurosurg. 2021.

Abstract

This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection.

Keywords: COVID-19; Guillain-Barre syndrome; Immunoglobulins; Nerve conduction; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart detailing the search protocol and the results after application of inclusion and exclusion criteria
See this image and copyright information in PMC

Comment in

References

    1. Munjal M, Das S, Chatterjee N, Setra AE, Govil D. Systemic involvement of novel coronavirus (COVID-19): a review of literature. Indian J Crit Care Med. 2020;24(7):565–569. doi: 10.5005/jp-journals-10071-23498. - DOI - PMC - PubMed
    1. da Rosa MR, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr. 2020:1–6. (in press) - PMC - PubMed
    1. Baig AM, Sanders EC. Potential neuroinvasive pathways of SARS-CoV-2: deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19) J Med Virol. 2020;92(10):1845–1857. doi: 10.1002/jmv.26105. - DOI - PMC - PubMed
    1. Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41(11):3039–3056. doi: 10.1007/s10072-020-04708-8. - DOI - PMC - PubMed
    1. Nguyen TP, Taylor RS. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021. Guillain Barre syndrome. 2020 Nov 19.

LinkOut - more resources